Molecular targeting agents in cancer therapy: science and society.
The inception of targeted agents has revolutionized the cancer therapy paradigm, both for physicians and patients. A large number of molecular targeted agents for cancer therapy are currently available for clinical use today. Many more are in making, but there are issues that remain to be resolved for the scientific as well as social community before the recommendation of their widespread use in may clinical scenarios can be done, one such issue being cost and cost effectiveness, others being resistance and lack of sustained efficacy. With the current knowledge about available targeted agents, the growing knowledge of intricate molecular pathways and unfolding of wider spectrum of molecular targets that can really matter in the disease control, calls for only the just use of the agents available now, drug companies need to make a serious attempt to reduce the cost of the agents. Research should focus on agents that show sustained responses in preclinical data. More needs to be done in laboratories and by the pharmaceutical industries, before we can truly claim to have entered a new era of targeted therapy in cancer care.
Section of Medical Oncology, Dubai Hospital, Dubai, UAE. asim.jshaikh@hotmail.com
Asim Jamal
AJ
Shaikh
D035843:Biomedical Research; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics / Q000941:ethics; D006801:Humans; D058990:Molecular Targeted Therapy / Q000191:economics*; D009369:Neoplasms / Q000628:therapy*